In a bid to thicken its blood-blocking solutions pipeline, Boston Scientific is harkening back to its hot-streak M&A trend from last year to acquire South Carolina-based embolization technology company Obsidio. Its hydrogel tech, which earned FDA clearance last month, can produce a blockade in an individual’s blood vessels to help slow or altogether stop blood flow to tumors or other abnormalities. Though financial terms of the deal remain undisclosed, Boston Scientific at least for now doesn’t expect any material impact to its 2022 earnings.
The Gel Embolic Material (GEM) tech from Obsidio is a semi-solid hydrogel meant to be inserted via catheter into a patient’s blood vessels in their peripheral vascular system, which comprises the veins delivering blood to places in the body other than the brain and heart. Its gel-based composition makes placement as well as conformation to each individual’s unique vascular structure as simple as possible.
Obsidio’s innovation will prove vital to Boston Scientific’s already bursting-at-the-seams portfolio of interventional oncology and embolization devices and materials. “The GEM technology combines benefits of currently available embolics, such as precise control of a solid and malleability of a liquid, to create a unique technology that offers procedural efficiency and a more personalized therapy for patients,” said Peter Pattison, the President of the aforementioned portfolio within Boston Scientific’s peripheral interventions segment.
